文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

青少年血脂异常治疗的算法。

Algorithms for Treating Dyslipidemia in Youth.

机构信息

Division of Diabetes and Endocrinology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, 6701 Fannin St. Ste 1020, Houston, TX, 77030, USA.

Division of Endocrinology, Department of Pediatrics, Harbor-UCLA Medical Center, The Lundquist Institute of Biomedical Innovation at Harbor-UCLA, Torrance, CA, 90509, USA.

出版信息

Curr Atheroscler Rep. 2023 Aug;25(8):495-507. doi: 10.1007/s11883-023-01122-1. Epub 2023 Jul 31.


DOI:10.1007/s11883-023-01122-1
PMID:37523052
Abstract

PURPOSE OF REVIEW: The goal of this article is to review algorithms for treating dyslipidemia in youth, discuss pitfalls, propose enhanced algorithms to address pitfalls, and consider future directions. RECENT FINDINGS: The presence of modifiable and non-modifiable cardiovascular disease (CVD) risk factors during childhood is associated with CVD-related events in adulthood. Recent data has shown that childhood initiation of statin therapy in youth < 18 years of age with familial hypercholesterolemia reduces the risk of adult CVD. However, pediatric dyslipidemia remains undertreated in part due to a lack of primary health care providers with adequate understanding of screening guidelines and pediatric lipidologists with experience in treatment and follow-up of this unique population. Management algorithms have been published by the National Heart, Lung, and Blood Institute and American Heart Association as tools to empower clinicians to manage dyslipidemia. We propose enhanced algorithms, which incorporate recently approved pharmacotherapy to address the management gaps. Future algorithms based upon clinical risk scores may enhance treatment and improve outcomes. Algorithms for dyslipidemia management which target youth < 18 years of age are tools which empower clinicians to manage dyslipidemia in this unique population. Enhanced algorithms may help address pitfalls. We acknowledge the need for further risk assessment tools in pediatrics for tailored dyslipidemia management.

摘要

目的综述:本文旨在综述青少年血脂异常的治疗方法,讨论其中的陷阱,提出改进的方法以克服这些陷阱,并探讨未来的发展方向。

最近的发现:儿童时期存在可改变和不可改变的心血管疾病(CVD)危险因素与成年期的 CVD 相关事件有关。最近的数据表明,在患有家族性高胆固醇血症的 18 岁以下青少年中,早期开始使用他汀类药物治疗可以降低成年期 CVD 的风险。然而,儿科血脂异常的治疗仍然不足,部分原因是缺乏对筛查指南有充分了解的初级保健提供者,以及在治疗和随访这一独特人群方面经验丰富的儿科脂质专家。美国国立心肺血液研究所和美国心脏协会已经发布了管理算法,作为赋予临床医生管理血脂异常能力的工具。我们提出了改进的算法,纳入了最近批准的药物治疗方法,以解决管理中的差距。基于临床风险评分的未来算法可能会改善治疗效果并改善预后。针对 18 岁以下青少年的血脂异常管理算法是赋予临床医生在这一独特人群中管理血脂异常能力的工具。改进的算法可能有助于克服陷阱。我们认识到需要在儿科领域进一步开发风险评估工具,以进行针对性的血脂异常管理。

相似文献

[1]
Algorithms for Treating Dyslipidemia in Youth.

Curr Atheroscler Rep. 2023-8

[2]
Improving Long-Term Outcomes of Youth With Lipid Abnormalities-Expanding the Role of Pediatric Endocrinologists.

J Clin Endocrinol Metab. 2019-10-1

[3]
The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update.

Can J Cardiol. 2022-8

[4]
Update on management of paediatric dyslipidaemia.

Curr Opin Endocrinol Diabetes Obes. 2023-2-1

[5]
Evaluation and Management of Lipids and Lipoproteins in Children and Adolescents.

Endocrinol Metab Clin North Am. 2022-9

[6]
Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease.

Clin Gastroenterol Hepatol. 2014-7

[7]
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.

Endocr Pract. 2017-4

[8]
Nutrition interventions for youth with dyslipidemia: a National Lipid Association clinical perspective.

J Clin Lipidol. 2022

[9]
Overview of Dyslipidemia in Childhood and Adolescence: Why Does It Matter and What Do We Do About It?

Pediatr Ann. 2021-1-1

[10]
Update on screening, etiology, and treatment of dyslipidemia in children.

J Clin Endocrinol Metab. 2014-9

引用本文的文献

[1]
Transition of care from childhood/adolescence to adulthood in familial hypercholesterolemia.

J Pediatr Endocrinol Metab. 2025-5-6

[2]
The Importance of Genetic Testing for Familial Hypercholesterolemia: A Pediatric Pilot Study.

Medicina (Kaunas). 2024-9-29

[3]
Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care.

Curr Atheroscler Rep. 2024-12

[4]
Myopathy in Statin-Treated Children and Adolescents: A Practical Approach.

Curr Atheroscler Rep. 2024-12

本文引用的文献

[1]
Update on management of paediatric dyslipidaemia.

Curr Opin Endocrinol Diabetes Obes. 2023-2-1

[2]
14. Children and Adolescents: Standards of Care in Diabetes-2023.

Diabetes Care. 2023-1-1

[3]
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?

Curr Atheroscler Rep. 2022-6

[4]
Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events.

N Engl J Med. 2022-5-19

[5]
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia.

Curr Atheroscler Rep. 2022-5

[6]
PDAY risk score predicts cardiovascular events in young adults: the CARDIA study.

Eur Heart J. 2022-8-7

[7]
Adherence with lipid screening guidelines in standard- and high-risk children and adolescents.

Am Heart J. 2021-2

[8]
Evinacumab for Homozygous Familial Hypercholesterolemia.

N Engl J Med. 2020-8-20

[9]
Pediatric Lipid Screening and Treatment in Canada: Practices, Attitudes, and Barriers.

Can J Cardiol. 2020-9

[10]
Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials.

Endocrine. 2020-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索